(Colorectal Cancer) Is Panitumumab + Lonsurf Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- May 29, 2023
- Read time: 1 minute
On May 18, 2023, Stefania Napolitano et al. from Università degli Studi della Campania "Luigi Vanvitelli" published in JAMA Oncology the efficacy and safety results of panitumumab + Lonsurf (trifluridine/tipiracil) as third-line treatment in refractory RAS wild-type recurrent colorectal cancer patients in the VELO Phase 2 clinical trial.
The VELO Phase 2 clinical trial was an open-label, randomized trial that randomized refractory RAS wild-type recurrent colorectal cancer patients 1:1 into the panitumumab + Lonsurf group and the Lonsurf monotherapy group. The primary endpoint was progression-free survival.
Patient characteristics for the 62 participants enrolled: median age was 65 years (range 39–81) for the panitumumab + Lonsurf group and (range 32–82) for the Lonsurf group; male percentage was 61.3% (N=19) for the panitumumab + Lonsurf group and 54.8% (N=17) for the Lonsurf group.
Trial results: the primary endpoint median progression-free survival was: panitumumab + Lonsurf group 4.0 months / Lonsurf group 2.5 months. The 6-month progression-free survival rate was: panitumumab + Lonsurf group 38.5% / Lonsurf group 13.0%. The 12-month progression-free survival rate was: panitumumab + Lonsurf group 15.4% / Lonsurf group 0%.
Based on the VELO trial results, Stefania Napolitano et al. stated: In refractory RAS wild-type recurrent colorectal cancer patients, panitumumab + Lonsurf as third-line treatment improved progression-free survival compared to Lonsurf monotherapy.
[Important Note] Medical Supporter's translations of overseas clinical trial data and pharmaceutical information are not intended to encourage participation in clinical trials or use of new drugs. The translated information is for reference only and not intended as medication guidelines. Please discuss with healthcare professionals and refer to the original text below the article for accurate information.
Source: https://jamanetwork.com/journals/jamaoncology/fullarticle/2805081
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4